Moreover, we examined the effect of KLF2 dysregulation on patient survival rates and found that only patients with adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), and sarcoma (SARC) had increased survival rates with high KLF2 expression. This evidence concerns the gene KLF2 and sarcoma.